Colonic immunopathogenesis of Clostridium difficile infections

Clinical and Vaccine Immunology

Volumn 21, Issue 4, 2014, Pages 509-517

  Darkoh, Charles ^a   Turnwald, Bradley P ^e   Koo, Hoonmo L ^d   Garey, Kevin W ^a,c,f   Jiang, Zhi Dong ^a   Aitken, Samuel L ^f   DuPont, Herbert L ^a,b,c,d,f  

^a UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c CHI ST LUKE S HEALTH BAYLOR ST LUKE S MEDICAL CENTER   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e OHIO WESLEYAN UNIVERSITY   (United States)

^f UNIVERSITY OF HOUSTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CALGRANULIN; CD40 LIGAND; COMPLEMENT COMPONENT C5A; CYTOKINE; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 13; INTERLEUKIN 16; INTERLEUKIN 23; INTERLEUKIN 27; INTERLEUKIN 8; LACTOFERRIN; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; AGED; ARTICLE; CELLULAR IMMUNITY; CHILD; CLOSTRIDIUM DIFFICILE INFECTION; CONCENTRATION (PARAMETERS); EFFECTOR CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FECES ANALYSIS; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; MEMORY T LYMPHOCYTE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RECURRENT DISEASE; TH1 CELL; TH2 CELL; VERY ELDERLY; CHEMISTRY; CLOSTRIDIUM INFECTION; COLON; FECES; IMMUNOLOGY; MICROBIOLOGY; MIDDLE AGED; PATHOLOGY; PEPTOCLOSTRIDIUM DIFFICILE; PRESCHOOL CHILD; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; COLON; CYTOKINES; FECES; FEMALE; HUMANS; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84897936165     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00770-13     Document Type: Article

References (32)

1. Loo VG, Poirier L, Miller MA, Oughton M, Libman MD, Michaud S, Bourgault AM, Nguyen T, Frenette C, Kelly M, Vibien A, Brassard P, Fenn S, Dewar K, Hudson TJ, Horn R, Rene P, Monczak Y, Dascal A. 2005. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N. Engl. J. Med. 353:2442-2449. http://dx.doi.org/10.1056/NEJMoa051639. (Pubitemid 41770165)
2. DuPont HL. 2011. The search for effective treatment of Clostridium difficile infection. N. Engl. J. Med. 364:473-475. http://dx.doi.org/10.1056/ NEJMe1013236.
3. Voth DE, Ballard JD. 2005. Clostridium difficile toxins: mechanism of action and role in disease. Clin. Microbiol. Rev. 18:247-263. http://dx.doi.org/10.1128/CMR.18.2.247-263.2005. (Pubitemid 40548293)
4. Thelestam M, Florin I. 1994. Assay of cytopathogenic toxins in cultured cells. Methods Enzymol. 235:679-690. http://dx.doi.org/10.1016/0076-6879(94) 35181-3.
5. Von Eichel-Streiber C, Boquet P, Sauerborn M, Thelestam M. 1996. Large clostridial cytotoxins-a family of glycosyltransferases modifying small GTP-binding proteins. Trends Microbiol. 4:375-382. http://dx.doi.org/10.1016/ 0966-842X(96)10061-5. (Pubitemid 26325127)
6. Steiner TS, Flores CA, Pizarro TT, Guerrant RL. 1997. Fecal lactoferrin, interleukin-1beta, and interleukin-8 are elevated in patients with severe Clostridium difficile colitis. Clin. Diagn. Lab. Immunol. 4:719-722. (Pubitemid 27501413)
7. Torres JF, Lyerly DM, Hill JE, Monath TP. 1995. Evaluation of formalin-inactivated Clostridium difficile vaccines administered by parenteral and mucosal routes of immunization in hamsters. Infect. Immun. 63:4619-4627.
8. Manabe YC, Vinetz JM, Moore RD, Merz C, Charache P, Bartlett JG. 1995. Clostridium difficile colitis: an efficient clinical approach to diagnosis. Ann. Intern. Med. 123:835-840. http://dx.doi.org/10.7326/0003-4819-123-11-199512010- 00004.
9. Desai D, Faubion WA, Sandborn WJ. 2007. Review article: biological activity markers in inflammatory bowel disease. Aliment. Pharmacol. Ther. 25:247-255. http://dx.doi.org/10.1111/j.1365-2036.2006.03184.x. (Pubitemid 46115394)
10. Schroder O, Naumann M, Shastri Y, Povse N, Stein J. 2007. Prospective evaluation of faecal neutrophil-derived proteins in identifying intestinal inflammation: combination of parameters does not improve diagnostic accuracy of calprotectin. Aliment. Pharmacol. Ther. 26:1035-1042. http: //dx.doi.org/10. 1111/j.1365-2036.2007.03457.x. (Pubitemid 47416301)
11. Guerrant RL, Araujo V, Soares E, Kotloff K, Lima AA, Cooper WH, Lee AG. 1992. Measurement of fecal lactoferrin as a marker of fecal leukocytes. J. Clin. Microbiol. 30:1238-1242.
12. Bjerke K, Halstensen TS, Jahnsen F, Pulford K, Brandtzaeg P. 1993. Distribution of macrophages and granulocytes expressing L1 protein (calprotectin) in human Peyer's patches compared with normal ileal lamina propria and mesenteric lymph nodes. Gut 34:1357-1363. http://dx.doi.org/10.1136/ gut.34.10.1357. (Pubitemid 23293619)
13. Roseth AG, Schmidt PN, Fagerhol MK. 1999. Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand. J. Gastroenterol. 34: 50-54. http://dx.doi.org/10.1080/00365529950172835.
14. Garey KW, Jiang ZD, Ghantoji S, Tam VH, Arora V, Dupont HL. 2010. A common polymorphism in the interleukin-8 gene promoter is associated with an increased risk for recurrent Clostridium difficile infection. Clin. Infect. Dis. 51:1406-1410. http://dx.doi.org/10.1086/657398.
15. Darkoh C, DuPont HL, Kaplan HB. 2011. Novel one-step method for detection and isolation of active-toxin-producing Clostridium difficile strains directly from stool samples. J. Clin. Microbiol. 49:4219-4224. http://dx.doi.org/10.1128/ JCM.01033-11.
16. Tixier E, Lalanne F, Just I, Galmiche JP, Neunlist M. 2005. Human mucosa/submucosa interactions during intestinal inflammation: involvement of the enteric nervous system in interleukin-8 secretion. Cell. Microbiol. 7:1798-1810. http://dx.doi.org/10.1111/j.1462-5822.2005.00596.x.
17. Jiang ZD, Garey KW, Price M, Graham G, Okhuysen P, Dao-Tran T, LaRocco M, DuPont HL. 2007. Association of interleukin-8 polymorphism and immunoglobulin G anti-toxin A in patients with Clostridium difficile-associated diarrhea. Clin. Gastroenterol. Hepatol. 5:964-968. http://dx.doi.org/10.1016/j.cgh.2007.04.018. (Pubitemid 47127029)
18. Iwakura Y, Ishigame H. 2006. The IL-23/IL-17 axis in inflammation. J. Clin. Invest. 116:1218-1222. http://dx.doi.org/10.1172/JCI28508.
19. Yen D, Cheung J, Scheerens H, Poulet F, McClanahan T, McKenzie B, Kleinschek MA, Owyang A, Mattson J, Blumenschein W, Murphy E, Sathe M, Cua DJ, Kastelein RA, Rennick D. 2006. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J. Clin. Invest. 116:1310-1316. http://dx.doi.org/10.1172/JCI21404.
20. Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, Hunte B, Vega F, Yu N, Wang J, Singh K, Zonin F, Vaisberg E, Churakova T, Liu M, Gorman D, Wagner J, Zurawski S, Liu Y, Abrams JS, Moore KW, Rennick D, de Waal-Malefyt R, Hannum C, Bazan JF, Kastelein RA. 2000. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 13:715-725. http://dx.doi.org/10.1016/S1074-7613(00)00070-4.
21. Parham C, Chirica M, Timans J, Vaisberg E, Travis M, Cheung J, Pflanz S, Zhang R, Singh KP, Vega F, To W, Wagner J, O'Farrell AM, McClanahan T, Zurawski S, Hannum C, Gorman D, Rennick DM, Kastelein RA, de Waal Malefyt R, Moore KW. 2002. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J. Immunol. 168:5699-5708. (Pubitemid 34556153)
22. Lankford CS, Frucht DM. 2003. A unique role for IL-23 in promoting cellular immunity. J. Leukoc. Biol. 73:49-56. http://dx.doi.org/10.1189/jlb. 0602326. (Pubitemid 36125674)
23. Buonomo EL, Madan R, Pramoonjago P, Li L, Okusa MD, Petri WA, Jr. 2013. Role of interleukin 23 signaling in Clostridium difficile colitis. J. Infect. Dis. 208:917-920. http://dx.doi.org/10.1093/infdis/jit277.
24. Kane SV, Sandborn WJ, Rufo PA, Zholudev A, Boone J, Lyerly D, Camilleri M, Hanauer SB. 2003. Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am. J. Gastroenterol. 98:1309-1314. http://dx.doi.org/10.1111/j.1572-0241.2003.07458.x. (Pubitemid 36741528)
25. Joshi S, Lewis SJ, Creanor S, Ayling RM. 2010. Age-related faecal calprotectin, lactoferrin and tumour M2-PK concentrations in healthy volunteers. Ann. Clin. Biochem. 47:259-263. http://dx.doi.org/10.1258/acb.2009.009061.
26. Dolwani S, Metzner M, Wassell JJ, Yong A, Hawthorne AB. 2004. Diagnostic accuracy of faecal calprotectin estimation in prediction of abnormal small bowel radiology. Aliment Pharmacol. Ther. 20:615-621. http://dx.doi.org/10.1111/j. 1365-2036.2004.02128.x. (Pubitemid 39279049)
27. Konikoff MR, Denson LA. 2006. Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease. Inflamm. Bowel Dis. 12:524-534. http://dx.doi.org/10.1097/00054725-200606000-00013.
28. Shastri YM, Bergis D, Povse N, Schafer V, Shastri S, Weindel M, Ackermann H, Stein J. 2008. Prospective multicenter study evaluating fecal calprotectin in adult acute bacterial diarrhea. Am. J. Med. 121:1099-1106. http://dx.doi.org/10.1016/j.amjmed.2008.06.034.
29. Eckert C, Barbut F. 2010. Clostridium-difficile-associated infections. Med. Sci. (Paris) 26:153-158. (In French.) http://dx.doi.org/10.1051/medsci/ 2010262153.
30. Murphy KM, Reiner SL. 2002. The lineage decisions of helper T cells. Nat. Rev. Immunol. 2:933-944. http://dx.doi.org/10.1038/nri954. (Pubitemid 37323214)
31. Abbas AK, Murphy KM, Sher A. 1996. Functional diversity of helper T lymphocytes. Nature 383:787-793. http://dx.doi.org/10.1038/383787a0. (Pubitemid 26372655)
32. Finkelman FD, Shea-Donohue T, Morris SC, Gildea L, Strait R, Madden KB, Schopf L, Urban JF, Jr. 2004. Interleukin-4- and interleukin-13-mediated host protection against intestinal nematode parasites. Immunol. Rev. 201:139-155. http://dx.doi.org/10.1111/j.0105-2896.2004.00192.x. (Pubitemid 39318449)